A short catalogue, on purpose.

Most of this category works like a menu. You arrive knowing the name of a compound, you type it in, and somebody writes it. The appeal is obvious and so is the problem: the thing you are actually paying for is a physician's judgement, and a menu is precisely the mechanism that removes it.

Whealth is built the other way round. You answer five clinical questions. A physician licensed in your state reads them and either signs or declines — and a decline arrives as an email with a reason in it, not as silence. Your card is authorised at checkout and charged only at the moment somebody approves. If nobody does, nothing is taken.

None of that is unusual. What is unusual is how little we have to sell you.

If the answer to "why you" is "we will sell you what others won't", that is not a company. It is a defendant.

There are two treatments here. Sermorelin, because it is the one flagship in this category whose regulatory position is genuinely uncomplicated. And a weight-management programme built on the branded, FDA-approved GLP-1 medicines rather than a compounded copy of them — which costs more, and which we do anyway, because the compounded supply is being withdrawn by regulation and discovering that mid-titration is a bad way to find out.

The third page is the one that matters. BPC-157 is the most requested compound in any gym and we do not dispense it. Rather than quietly leave it off the shelf, we publish the page, state the grade, and set out the evidence and the compounding status with citations so you can disagree with us on the facts. It is the page we would delete if we were optimising for revenue, and it is the reason to trust the other two.

We are not a pharmacy and not a clinic. We are the layer that carries an intake to a prescriber and a prescription to a pharmacy without losing anything on the way, and we would rather be short of products than short of reasons.